News

Researchers have uncovered a mechanism by which Pseudomonas aeruginosa and Aspergillus fumigatus — two common infection-causing microbes in the lungs of people with cystic fibrosis (CF) — are able to…

SARS-CoV-2, the virus that causes COVID-19, appears to induce the loss of CFTR protein in a cell-based airway model, replicating the inflammatory state seen in the lungs of people with cystic fibrosis (CF), a study suggested. Treating cells with cardiac glycosides, a class of medicines that block the virus…

Destiny Pharma is launching a research program to test a potential therapy derived from its XF drug platform for methicillin-resistant Staphylococcus aureus (MRSA) lung infections in people with cystic fibrosis (CF). The program will test the potency of an experimental treatment known as XF-73 in MRSA samples from CF…

The first healthy volunteers have been dosed in Australia as part of two separate Phase 1 clinical trials of SION-719 and SION-451 — two second-generation NBD1 stabilizers that Sionna Therapeutics is developing to restore function to the CFTR protein, which is faulty in cystic fibrosis (CF). The goal…

Families in the U.S. living with cystic fibrosis (CF) who’ve been affected by food insecurity feel that financial constraints imposed by the disease contribute to the problem and that government support programs are insufficient, interviews with patients and caregivers suggest. Those interviewed report feeling stigma and embarrassment…

Cystic Fibrosis Foundation (CFF) grants will help fund four programs that support the well-being of people with cystic fibrosis (CF). The awards, given through the foundation’s ninth annual Impact Grants program, provide up to $10,000 to individuals and nonprofit organizations in the CF community. Since the program started…

Positivo Biotechnology, a company working to develop new gene therapy technologies for cystic fibrosis (CF), has been selected as the winner of this year’s Golden Ticket Award. The award, launched last year by the Cystic Fibrosis Foundation and the University of California, Berkeley’s Bakar Labs, aims to…

Treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) may ease anxiety and depression symptoms in adults with cystic fibrosis (CF), a study found. A higher proportion of patients experienced a clinically significant easing in both anxiety and depression symptoms than those who saw their symptoms worsen. Those with clinically significant changes in…

Even though most people with cystic fibrosis (CF) place considerable importance on being prepared in making decisions about a lung transplant, many lack knowledge of the procedure and speak of feeling unprepared, especially those of lower socioeconomic status, a survey of adults at a University of Washington CF clinic…

Most infants with cystic fibrosis (CF) must be fed fortified milk, that is, breast milk, formula, or a combination of both, within the first six months of life to achieve normal growth by age 3, a study suggests. This lets babies receive all the benefits from breast milk, plus…